Cerus Corporation Appoints David N. Cook as Vice President, Biotherapeutic Research and Development.Business Editors/Medical Writers CONCORD, Calif.--(BW HealthWire)--Oct. 4, 2001 Cerus Corporation (Nasdaq:CERS) today announced the appointment of David N. Cook, Ph.D., to the position of vice president, Biotherapeutic Research and Development. Dr. Cook, an accomplished scientist and proven medical products executive, rejoins Cerus with over 11 years of research and development experience, specifically in the area of transfusion medicine transfusion medicine Blood banking A subspecialty of clinical pathology or internal medicine which is involved in Pt management through administration of blood cells and blood products including fresh-frozen plasma and cryoprecipitate; TM specialists are versant in , oncology and stem cell transplantation Stem Cell Transplantation Definition Stem cells are basic human cells that reproduce (replicate) easily, providing a continuous source of new, sometimes different types of cells. . In this newly-created position, Dr. Cook will lead the company's development of biotherapeutic products. "We are extremely pleased to have Dr. Cook, with his extensive product and business development experience, return to our management team," said Stephen T. Isaacs, president and chief executive officer of Cerus. "While we remain focused on the near-term commercialization of our INTERCEPT Blood Systems for inactivating pathogens in blood, we believe it is essential to build our product pipeline to sustain our future growth. Dr. Cook will focus his efforts on leveraging the therapeutic potential of our proprietary Helinx technology. He will also evaluate other opportunities that complement our existing scientific and development expertise and address significant unmet medical needs." Dr. Cook, 43, joins Cerus from Eligix Incorporated where he held the position of senior vice president of Research and Development. Under his leadership the company gained European approval for their BCell-HDM and Tcell-HDM devices, medical products developed to improve the outcome of stem cell transplantation. Prior to Eligix, Dr. Cook was the vice president of Commercialization and the director of Red Cell Development for Cerus Corporation. Dr. Cook also spent three years as a postdoctoral scientist for the Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory and Lawrence Livermore National Laboratory, scientific research centers run by the Univ. of California, located in Berkeley, Calif., and Livermore, Calif., respectively. , where he studied DNA supercoiling and discovered genes in bacteria important in drug resistance. He holds an A.B. in American Studies from Harvard University Harvard University, mainly at Cambridge, Mass., including Harvard College, the oldest American college. Harvard College Harvard College, originally for men, was founded in 1636 with a grant from the General Court of the Massachusetts Bay Colony. , a B.S. in Chemistry from California State University Enrollment  , Long Beach, and a Ph.D. in Chemistry from the University of California, Berkeley The University of California, Berkeley is a public research university located in Berkeley, California, United States. Commonly referred to as UC Berkeley, Berkeley and Cal . ABOUT CERUS Cerus Corporation is developing medical systems and therapeutics based on its proprietary Helinx(TM) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the blood products used for transfusion. These INTERCEPT Blood Systems, based on the company's Helinx technology, are designed to inactivate in·ac·ti·vate v. 1. To render nonfunctional. 2. To make quiescent. in·ac  ti·va viruses, bacteria, other pathogens and white blood cells White blood cellsA group of several cell types that occur in the bloodstream and are essential for a properly functioning immune system. Mentioned in: Abscess Incision & Drainage, Bone Marrow Transplantation, Complement Deficiencies . The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases. Statements in this news release regarding product development and product potential are forward-looking statements that involve risks and uncertainties. Actual results could differ materially from the above forward-looking statements as a result of certain factors, including the risks and uncertainty of the timing and results of clinical trials and other development activities, actions by regulatory authorities at any stage of the development process, additional financing activities, market acceptance of any products, competitive conditions and other factors discussed in the company's most recent reports on Forms 10K, 10Q and other filings with the Securities and Exchange Commission. Note to Editors: Helinx is a trademark of Cerus Corporation. INTERCEPT Blood System is a trademark of Baxter International Baxter International Inc. (NYSE: BAX), is a global healthcare company with 48,000 employees and 2006 sales of US$10.4 billion. Its headquarters is in Deerfield, Illinois. , Inc. (NYSE NYSE See: New York Stock Exchange :BAX). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion